Skip to main navigation Skip to search Skip to main content

Enriching for Tumor-Reactive CD8 TIL with CD39/103 Markers: Implications for TIL Therapy

Research output: Contribution to journal › Article

Original languageAmerican English
JournalArticles, Abstracts, and Reports
StatePublished - Oct 20 2021

Cite this